Namita Sood, M.D., F.C.C.P.
Director, UC Davis Advanced Lung Disease Program
Director, Pulmonary Hypertension Clinical Trials
Co- Director, UC Davis Pulmonary Hypertension Program
Professor of Medicine, Division of Pulmonary, Critical Care & Sleep Medicine
To see if Namita Sood is accepting new patients, or for assistance finding a UC Davis doctor, please call 800-2-UCDAVIS (800-282-3284).
Locations and Contact
UC Davis Medical Group - Sacramento (J Street)
Pulmonary, Critical Care and Sleep Medicine
2825 J St.
Sacramento, CA 95816
Phone: 916-734-8230
Fax: 916-734-4582
Additional Numbers
Clinic Phone
Clinic Fax
Physician Referrals
Philosophy of Care
I believe that it is a privilege to be a physician. I work every day to provide the best medical advice to my ability and develop treatment plan with the patient based on their goals and expectations.
Clinical Interests
Dr. Sood is a Pulmonary, Critical Care specialist offering care for patients with advanced lung disease. She has special interest and expertise in pulmonary vascular disease including pulmonary hypertension, pulmonary embolism, lung disease related to rheumatological disease and sickle cell anemia.
Research/Academic Interests
Dr. Sood's research interest focuses on new treatments for pulmonary hypertension, venotheomboembolism and interstitial lung disease.
Division
Pulmonary, Critical Care, and Sleep Medicine
Center/Program Affiliation
Medical School
M.B.B.Ch., Al Fateh University, Tripoli, Libya 1988
Internship
Internal Medicine, University of Missouri - Columbia, Columbia MO 1992-1993
Residency
Internal Medicine, University of Missouri - Columbia, Columbia MO 1993-1995
Fellowship
Pulmonary/Critical Care, University of North Carolina, Chapel Hill NC 1996-1999
Best Doctors in America, 2005, 2007, 2009, 2011, 2013, 2015, 2017, 2021
Distinguished Chest Educator of the American College of Chest Physician, 2019
Best Physicians in America, 2016
Excellence in Teaching, Ohio state University, 2016
Sood N, Murin S. Lipoid Pneumonia: Fat Chance of Making the Diagnosis? Chest. 2021 Aug;160(2):407-408. doi:10.1016/j.chest.2021.03.054. PMID:34366027.
Rahaghi FF, Allen RP, Balasubramanian VP, Chakinala MM, Elwing JM, Feldman J, Leary PJ, Rischard F, Safdar Z, Sood N, Oudiz RJ. An expert panel delphi consensus statement on patient selection and management for transitioning between oral and inhaled treprostinil. Pulm Pharmacol Ther. 2021 Feb;66:101979. doi:10.1016/j.pupt.2020.101979. Epub 2020 Nov 28. PMID:33259923.
Salahuddin M, Mathew R, Zhao B, Sood N. A Previously Healthy Policeman with Persistent Fevers, Pulmonary Infiltrates, and Multiorgan Failure. Ann Am Thorac Soc. 2020 Sep;17(9):1154-1157. doi:10.1513/AnnalsATS.202004-392CC. PMID:32870061.
Ghofrani HA, Grünig E, Jansa P, Langleben D, Rosenkranz S, Preston IR, Rahaghi F, Sood N, Busse D, Meier C, Humbert M. Efficacy and safety of riociguat in combination therapy for patients with pulmonary arterial hypertension (PATENT studies). Pulm Circ. 2020 Jul 16;10(3):2045894020942121. doi:10.1177/2045894020942121. PMID:32728421.
Preston IR, Burger CD, Bartolome S, Safdar Z, Krowka M, Sood N, Ford HJ, Battarjee WF, Chakinala MM, Gomberg-Maitland M, Hill NS. Ambrisentan in portopulmonary hypertension: A multicenter, open-label trial. J Heart Lung Transplant. 2020 May;39(5):464-472. doi:10.1016/j.healun.2019.12.008. Epub 2020 Jan 21. PMID:32008947.
Torres F, Farber H, Ristic A, McLaughlin V, Adams J, Zhang J, Klassen P, Shanahan W, Grundy J, Hoffmann I, Cabell C, Escribano Subías P, Sood N, Keogh A, D'Souza G, Rubin L. Efficacy and safety of ralinepag, a novel oral IP agonist, in PAH patients on mono or dual background therapy: results from a phase 2 randomised, parallel group, placebo-controlled trial. Eur Respir J. 2019 Oct 10;54(4):1901030. doi:10.1183/13993003.01030-2019. PMID:31391223.
Homsy E, Alghothani L, Chui DHK, Sood N. An Unusual Case of Low Hemoglobin Oxygen Saturation. Ann Am Thorac Soc. 2019 Jun;16(6):756-759. doi:10.1513/AnnalsATS.201811-829CC. PMID:31149860.
Sood N, Aranda A, Platt D, LaRose A, Kleinjung F, O'Brien G. Riociguat improves health-related quality of life for patients with pulmonary arterial hypertension: results from the phase 4 MOTION study. Pulm Circ. 2019 Jan-Mar;9(1):2045894018823715. doi:10.1177/2045894018823715. Epub 2018 Dec 21. PMID:30574833.
Bartolome SD, Sood N, Shah TG, Styrvoky K, Torres F, Chin KM. Mortality in Patients With Pulmonary Arterial Hypertension Treated With Continuous Prostanoids. Chest. 2018 Sep;154(3):532-540. doi:10.1016/j.chest.2018.03.050. Epub 2018 Apr 19. PMID:29679599.
Von Visger TT, Kuntz KK, Phillips GS, Yildiz VO, Sood N. Quality of life and psychological symptoms in patients with pulmonary hypertension. Heart Lung. 2018 Mar-Apr;47(2):115-121. doi:10.1016/j.hrtlng.2017.12.004. Epub 2018 Feb 1. PMID:29361341.
Hill NS, Rahaghi FF, Sood N, Frey R, Ghofrani HA. Individual dose adjustment of riociguat in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. Respir Med. 2017 Aug;129:124-129. doi:10.1016/j.rmed.2017.05.005. Epub 2017 May 15. PMID:28732819.